DOP058 Pharmacokinetic and pharmacodynamic relationship and immunogenicity of vedolizumab in adults with inflammatory bowel disease: Additional results from the GEMINI 1 and 2 studiesM. Rosario, Irving H. Fox, Brian G. Feagan et al.|Journal of Crohn s and Colitis|2014Cited by 24
P323 Sustained therapeutic benefit of vedolizumab throughout 1 year in ulcerative colitis in GEMINI I, a randomized, placebo-controlled, double-blind, multicenter trialW. Sandborn, Irving H. Fox, B E Sands et al.|Journal of Crohn s and Colitis|2013Cited by 6
P385 Population pharmacokinetic modelling of vedolizumab in patients with ulcerative colitis or Crohn's diseaseM. Rosario, A. Milton, Nathanael L. Dirks et al.|Journal of Crohn s and Colitis|2014Cited by 6
P488 Exposure-response relationship of vedolizumab after 6 weeks of treatment in adults with Crohn's diseaseM. Rosario, Marc R. Gastonguay, Irving H. Fox et al.|Journal of Crohn s and Colitis|2014Cited by 3